How to determine whether Pralsetinib is resistant or ineffective

Pralsetinib is a selective tyrosine kinase inhibitor targeting RET gene fusions or mutations. It is widely used to treat patients with RET-positive non-small cell lung cancer and thyroid cancer. Although platinib shows significant efficacy in many patients, as the treatment time is prolonged, some patients may develop drug resistance or treatment failure. Timely judgment of drug resistance is of great significance for adjusting treatment plans and prolonging patient survival.

First of all, the most direct basis for judging platinib resistance is tumor progression shown by imaging examinations. Regular imaging evaluations such as CT, MRI or PET-CT can be performed regularly to observe the size of the tumor and the appearance of new lesions. If the tumor continues to grow or new metastases appear, it may indicate that the drug has failed or developed drug resistance. In addition, persistent increases in tumor marker levels may also reflect increased disease activity.

Secondly, the worsening of clinical symptoms is also an important signal for judging drug resistance. If the patient's original symptoms worsen, or new general discomfort such as pain, difficulty breathing, significant weight loss, etc. occurs, it may indicate an increase in tumor burden and a decrease in drug efficacy. Changes in clinical manifestations should be comprehensively evaluated in conjunction with imaging findings.

Third, with the development of drug resistance, some patients' tumors may develop new gene mutations or activate signaling pathways, resulting in the weakening of platinib's inhibitory effect. Molecular testing through liquid biopsy or tissue biopsy can detect secondary mutations, bypass activation or other resistance mechanisms, providing a basis for subsequent adjustments to treatment options.

In summary, the judgment of platinib resistance or failure requires a combination of imaging examinations, clinical symptom changes, and molecular detection results. Early identification of drug resistance can help doctors promptly adjust treatment strategies, such as changing targeted drugs, combining chemotherapy or immunotherapy, to optimize patient prognosis.

Reference materials:https://www.drugs.com/